KdT Ventures is the standard in early-stage biotech investing. We help founders and their companies re-architect the world at a molecular level.
StrideBio is a gene therapy company developing immune-evading viral vectors to expand the treatable patient population.
"Phil started on the ground floor at StrideBio, helping us compile and evaluate a clinical pipeline that highlighted our technology's key strengths, and he has seen the evolution of these projects as they begin to come to life. His ability to synthesize scientific, commercial, and medical information provides invaluable input to our discussions."
Aravind Asokan, PhD
Ribometrix has proprietary methods to determine 3D RNA structures and develop structure-based drug screening.
"Phil was instrumental in identifying high-impact targets for our platform technology, and his work ultimately allowed us to establish the interest of and obtain a major funding commitment from our first strategic venture investor.
Phil played several critical roles during early stages of our start up, including honing pitches, developing a 5-year financial model, and identifying targets of broad interest to major investors. Phil's contributions categorically enabled us to land a multi-million-dollar seed investment."
Kevin Weeks, PhD
Company In Development
Information coming soon.